High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data

Vittorio Gebbia, Maria Rosaria Valerio, Mariacarmela Santarpia, Gianfranco Mancuso, Andrea Girlando, Nicolo Borsellino, Vittorio Gebbia, Stefano Pergolizzi, Dario Piazza, Antonio Pontoriero, Giuseppe Altavilla, Gianfranco Mancuso

Risultato della ricerca: Article

Abstract

Background/Aim. Local ablative treatments foroligo-progressive, EGFR mutated non-small cell lung cancer(mut-NCSLC) may improve long-term disease control andsurvival. We analyzed the efficacy of hypo-fractionated, highdose radiation therapy (HDRT), in association with prolongedEGFR tyrosine kinase inhibitors (TKI) in oligo-progressive,EGFR mutant-NSCLC. Patients and Methods. Progressionfree survival-1 (PFS-1, date from initiation of TKI therapyuntil oligo-progression or death), and progression-freesurvival-2 (PFS-2, date of focal progression until furtherprogression or death) were evaluated. Results. Thirty-sixpatients were analyzed. The median PFS 1 was 12.5 months.HDHRT consisted of intensity-modulated RT and stereotacticRT in 23 (64%) and 13 (36%) patients respectively. Themedian PFS 2 was 6.3 months. Overall survival was 38.7months. Conclusion. Hypo-fractionated HDRT plus TKItherapy, is associated with a significant prolongation ofdisease control (overall PFS: 18.8 months), with manageableside effects. These real-world data support the use of localablative approaches in oligo-progressive EGFR mut-NSCLC.
Lingua originaleEnglish
pagine (da-a)2009-2014
Numero di pagine6
RivistaIn Vivo
Volume34
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Fingerprint Entra nei temi di ricerca di 'High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data'. Insieme formano una fingerprint unica.

  • Cita questo

    Gebbia, V., Valerio, M. R., Santarpia, M., Mancuso, G., Girlando, A., Borsellino, N., Gebbia, V., Pergolizzi, S., Piazza, D., Pontoriero, A., Altavilla, G., & Mancuso, G. (2020). High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data. In Vivo, 34, 2009-2014.